Advertisement

Important Roles of ERCC1 in DNA Repair and Targeted Therapy

  • Jennifer J. Hu
  • Joseph de la Garza
  • Sathish K. Srinivasan
  • Ann Alyssa Kurian
  • Feng Gong
Chapter
Part of the Cancer Drug Discovery and Development book series (CDD&D, volume 72)

Abstract

The ERCC1 protein (excision repair cross-complementing rodent repair deficiency, complementation group 1) forms a heterodimer with the Xeroderma pigmentosum group F (XPF) endonuclease (also known as ERCC4), and the heterodimeric endonuclease catalyzes the 5′ incision in the process of excising the DNA lesion. The ERCC1–XPF heterodimer has an important role in genome maintenance. While most of the DNA repair proteins function only in a specific repair pathway, ERCC1–XPF is involved in multiple DNA repair pathways and telomere maintenance, making this heterodimer not only an attractive therapeutic target, but also a biomarker to predict treatment outcome (Fig. 2.3).

Keywords

Epithelial Ovarian Cancer Nucleotide Excision Repair ERCC1 Expression Nucleotide Excision Repair Pathway ERCC1 mRNA 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Tripsianes K et al (2005) The structure of the human ERCC1/XPF interaction domains reveals a complementary role for the two proteins in nucleotide excision repair. Structure 13(12):1849–1858PubMedCrossRefGoogle Scholar
  2. 2.
    Tsodikov OV et al (2005) Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease XPF-ERCC1. Proc Natl Acad Sci USA 102(32):11236–11241PubMedCrossRefGoogle Scholar
  3. 3.
    Enzlin JH, Scharer OD (2002) The active site of the DNA repair endonuclease XPF-ERCC1 forms a highly conserved nuclease motif. EMBO J 21(8):2045–2053PubMedCrossRefGoogle Scholar
  4. 4.
    de Boer J, Hoeijmakers JH (2000) Nucleotide excision repair and human syndromes. Carcinogenesis 21(3):453–460PubMedCrossRefGoogle Scholar
  5. 5.
    Cleaver JE, Lam ET, Revet I (2009) Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity. Nat Rev Genet 10(11):756–768PubMedCrossRefGoogle Scholar
  6. 6.
    Sargent RG et al (1997) Recombination-dependent deletion formation in mammalian cells deficient in the nucleotide excision repair gene ERCC1. Proc Natl Acad Sci USA 94(24):13122–13127PubMedCrossRefGoogle Scholar
  7. 7.
    Adair GM et al (2000) Role of ERCC1 in removal of long non-homologous tails during targeted homologous recombination. EMBO J 19(20):5552–5561PubMedCrossRefGoogle Scholar
  8. 8.
    Kuraoka I et al (2000) Repair of an interstrand DNA cross-link initiated by ERCC1-XPF repair/recombination nuclease. J Biol Chem 275(34):26632–26636PubMedCrossRefGoogle Scholar
  9. 9.
    Fisher LA, Bessho M, Bessho T (2008) Processing of a psoralen DNA interstrand cross-link by XPF-ERCC1 complex in vitro. J Biol Chem 283(3):1275–1281PubMedCrossRefGoogle Scholar
  10. 10.
    Zhu XD et al (2003) ERCC1/XPF removes the 3′ overhang from uncapped telomeres and represses formation of telomeric DNA-containing double minute chromosomes. Mol Cell 12(6):1489–1498PubMedCrossRefGoogle Scholar
  11. 11.
    Munoz P et al (2005) XPF nuclease-dependent telomere loss and increased DNA damage in mice overexpressing TRF2 result in premature aging and cancer. Nat Genet 37(10):1063–1071PubMedCrossRefGoogle Scholar
  12. 12.
    Siegel R et al (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61(4):212–236PubMedCrossRefGoogle Scholar
  13. 13.
    Li F et al (2010) Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol 33(5):489–494PubMedCrossRefGoogle Scholar
  14. 14.
    Han JY et al (2011) DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma. Cancer 117(14):3201–3208PubMedCrossRefGoogle Scholar
  15. 15.
    Ren S et al (2010) High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients. Cancer Invest 28(10):1078–1083PubMedCrossRefGoogle Scholar
  16. 16.
    Holm B et al (2009) Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol 27(26):4254–4259PubMedCrossRefGoogle Scholar
  17. 17.
    Bepler G et al (2011) ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol 178(1):69–78PubMedCrossRefGoogle Scholar
  18. 18.
    Reynolds C et al (2009) Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 27(34):5808–5815PubMedCrossRefGoogle Scholar
  19. 19.
    Vilmar AC, Santoni-Rugiu E, Sorensen JB (2010) ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 21(9):1817–1824PubMedCrossRefGoogle Scholar
  20. 20.
    Knez L et al (2011) Predictive value of multidrug resistance proteins, topoisomerases II and ERCC1 in small cell lung cancer: a systematic review. Lung Cancer 72(3):271–279PubMedCrossRefGoogle Scholar
  21. 21.
    Hoskins WJ et al (1994) The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170(4):974–979, discussion 979–980PubMedGoogle Scholar
  22. 22.
    Ozols RF et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17):3194–3200PubMedCrossRefGoogle Scholar
  23. 23.
    Krivak TC et al (2011) Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study. Gynecol Oncol 122(1):121–126PubMedCrossRefGoogle Scholar
  24. 24.
    Kang S et al (2006) Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med 38(3):320–324PubMedGoogle Scholar
  25. 25.
    Smith S et al (2007) ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 25(33):5172–5179PubMedCrossRefGoogle Scholar
  26. 26.
    Krivak TC et al (2008) Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol 26(21):3598–3606PubMedCrossRefGoogle Scholar
  27. 27.
    Darcy KM, Tian C, Reed E (2007) A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. Cancer Res 67(9):4474–4481PubMedCrossRefGoogle Scholar
  28. 28.
    Scheil-Bertram S et al (2010) Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma. Gynecol Oncol 119(2):325–331PubMedCrossRefGoogle Scholar
  29. 29.
    Steffensen KD, Waldstrom M, Jakobsen A (2009) The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int J Gynecol Cancer 19(5):820–825PubMedCrossRefGoogle Scholar
  30. 30.
    Chua W et al (2009) Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer 101(6):998–1004PubMedCrossRefGoogle Scholar
  31. 31.
    Liang J et al (2010) The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer. Cancer Chemother Pharmacol 66(3):493–500PubMedCrossRefGoogle Scholar
  32. 32.
    Fareed KR et al (2010) Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer 102(11):1600–1607PubMedCrossRefGoogle Scholar
  33. 33.
    Maithel SK et al (2011) Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection. Ann Surg Oncol 18:2699–2705PubMedCrossRefGoogle Scholar
  34. 34.
    Hoffmann AC et al (2010) MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 12(8):628–636PubMedGoogle Scholar
  35. 35.
    Ko JC et al (2010) Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2. Lung Cancer 69(2):155–164PubMedCrossRefGoogle Scholar
  36. 36.
    Ko JC et al (2011) Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine. Biochem Pharmacol 81(5):680–690PubMedCrossRefGoogle Scholar
  37. 37.
    Chen YY et al (2010) Emodin, aloe-emodin and rhein induced DNA damage and inhibited DNA repair gene expression in SCC-4 human tongue cancer cells. Anticancer Res 30(3):945–951PubMedGoogle Scholar
  38. 38.
    Yacoub A et al (2003) Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 159(4):439–452PubMedCrossRefGoogle Scholar
  39. 39.
    Li XL et al (2010) The sequence-dependent cytotoxic effect of trastuzumab in combination with 5-Fluorouracil or cisplatin on gastric cancer cell lines. Cancer Invest 28(10):1038–1047PubMedCrossRefGoogle Scholar
  40. 40.
    Guirouilh-Barbat J, Antony S, Pommier Y (2009) Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition. Mol Cancer Ther 8(7):2007–2014PubMedCrossRefGoogle Scholar
  41. 41.
    Soares DG et al (2011) Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells. Mol Cancer Ther 10(8):1481–1489PubMedCrossRefGoogle Scholar
  42. 42.
    Barakat KH et al (2009) Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening approach. J Mol Graph Model 28(2):113–130PubMedCrossRefGoogle Scholar
  43. 43.
    Orelli B et al (2010) The XPA-binding domain of ERCC1 is required for nucleotide excision repair but not other DNA repair pathways. J Biol Chem 285(6):3705–3712PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  • Jennifer J. Hu
    • 1
    • 2
    • 3
    • 4
  • Joseph de la Garza
    • 1
    • 5
  • Sathish K. Srinivasan
    • 2
  • Ann Alyssa Kurian
    • 1
  • Feng Gong
    • 1
    • 4
  1. 1.Sylvester Comprehensive Cancer CenterUniversity of Miami Miller School of MedicineMiamiUSA
  2. 2.Interdepartmental Program in Human Genetics and GenomicsUniversity of Miami Miller School of MedicineMiamiUSA
  3. 3.Department of Epidemiology and Public HealthUniversity of Miami Miller School of MedicineMiamiUSA
  4. 4.Biochemistry and Molecular BiologyUniversity of Miami Miller School of MedicineMiamiUSA
  5. 5.Department of Obstetrics and GynecologyUniversity of Miami Miller School of MedicineMiamiUSA

Personalised recommendations